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Abstract
Introduction: The potential association of the ABO blood
group with the risk of COVID-19 and its severity has attracted
a lot of interest since the start of the pandemic. While a number of studies have reported an increased risk associated with
blood type A and a reduced risk with type O, other studies
have not found a significant effect. This study aimed to define
the prevalence of different ABO blood groups in hospitalized
COVID-19 patients in the Louisville, KY area and to investigate whether an association exists between the blood group
and disease severity.
Methods: This was a retrospective observational study of
380 patients with SARS-CoV-2 infection hospitalized to eight
of the adult hospitals in the city of Louisville. Patients were divided into four different groups according to their ABO blood
type. Demographic characteristics and clinical variables, including laboratory data as well as clinical outcomes were
compared.
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Results: Type O was the most common blood group among
the hospitalized patients (51%) followed by type A (31%), B
(14%) and AB (4%). The observed blood group distribution
among the patients was not significantly different from the distribution expected when compared to a population of similar
racial/ethnic composition. No significant associations were
found between the blood group and comorbidities, inflammatory biomarkers as well as with recorded outcomes, including
the mortality rate and the length of the hospital stay.
Conclusions: The data from hospitalized patients in
Louisville is not consistent with the ABO blood group having a significant effect as a risk or severity factor for COVID19, but it is representative of its prevalence among different
racial/ethnic populations.
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Introduction
As of January 27, 2021, there have been more than 99
million confirmed cases of COVID-19, including over
2.15 million deaths around the world.[1] COVID-19 can
exhibit a wide variety of clinical presentations, ranging from asymptomatic cases to very severe and critical
cases with acute respiratory distress syndrome (ARDS),
septic shock, multiorgan failure and death.[2–5] Therefore, it is important to study the demographic, clinical
and genetic factors that allow the identification of people at increased risk of suffering serious manifestations.
Age, sex, hypertension, diabetes, and chronic vascular
and respiratory diseases have already been identified
as important risk factors for the severity of COVID19.[2–6]
Efforts to understand the etiology and pathophysiology of the disease have led to the examination
of other coronaviruses, including SARS coronavirus
(SARS-CoV-1) and the Middle East respiratory syndrome coronavirus (MERS-CoV). Interestingly, several
studies on SARS-CoV-1 suggested a relationship between infection risk and blood type, with blood type
O being somewhat protective against the virus.[7, 8]
Consistent with such findings, several recent reports
have also suggested the existence of an association between ABO blood types and COVID-19 risk.[9–11] For
example, several groups in China reported an overrepresentation of individuals with blood group A and
an under-representation of those with blood group O
among hospitalized patients with COVID-19 compared
to blood group distribution in the regions of Wuhan
and Shenzen.[9–11] The results suggest a higher risk
for individuals with blood type A to contract the disease and a lower risk for individuals with blood type
O. However, most of these reports did not find a significant association with disease severity or mortality.[12]
Later, a report based on a Genome-Wide Association
study (GWAS) reported a significant association of two
loci, 3p21.31 and 9q34.2, the latter encoding the blood
group ABO antigens, with the risk of COVID-19 among
hospitalized patients in Italy and Spain. Agreeing with
previous reports, this study found again a higher risk
for blood type A and lower for type O.[13]
However, the matter of the association of the ABO
blood group with risk or severity of COVID-19 has
not been definitively settled, as several studies have reported divergent or conflicting results. For example, a
study of over 14,000 individuals tested in the New York
Presbyterian Hospital System reported a slightly increased infection prevalence among patients with nonO blood types. Moreover, when compared with patients with blood type O, the risk of intubation was decreased for patients with blood type A but increased in
those of blood groups AB and B, and while the risk of
death was decreased for those with blood types A and
B, it was increased for those with blood type AB.[14]
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Furthermore, Latz et al. [15] found no significant association of blood group with peak levels of inflammatory markers or outcomes in COVID-19 patients. Multivariate analyses found that individuals with Rh+ blood
were more likely to test positive and that those with
blood types AB and B, but not A, were more likely
to test positive compared with type O.[15] In another
study, Leaf et al. did find an over-representation of type
A blood and an under-representation of type O blood
among 3,239 critically ill COVID-19 patients, but this
was true only for non-Hispanic white patients, and not
for Blacks or Hispanics.[16] Finally, in a study of 428
COVID-19 patients at the University of Cincinnati Hospital System, Mendy et al. did not find an association
of blood group with hospitalization or disease severity.[17]
Prompted by the contrasting conclusions of several reports, we undertook this study with the aim of examining the association between the ABO blood groups and
the risk and severity of COVID-19 using data from 380
hospitalized patients in the Louisville, KY, area.

Methods
Study Design, Subjects, and Setting
This was a retrospective study including 380 patients
with a diagnosis of SARS-CoV-2 infection and blood
group data, who were hospitalized in any of the
eight adult hospitals in the City of Louisville, KY. The
study group was part of a larger study of hospitalized
COVID-19 patients that started on March 5, 2020 and
ended on July 1, 2020.[18]
Human Subjects Protection
The study was approved by the Institutional Review
Board (IRB) at the University of Louisville Human Subjects Research Protection Program Office (IRB number
20.0257) and by the research offices at each participating hospital. The study was exempt from informed
consent.
Data Collection
Data were abstracted from hospital electronic medical records. Collected data included patient age; sex;
race/ethnicity; body mass index; medical and social
history; physical examination findings; laboratory findings, including blood type, chest radiographs and chest
CT findings; medications; intensive care unit (ICU)
admission; and need for invasive mechanical ventilation (IMV). Race/ethnicity was categorized as Black,
Hispanic, non-Hispanic white (white, NH), Asian and
Other.
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Study Definitions
SARS-CoV-2 infection: A patient hospitalized with a
positive SARS-CoV-2 reverse transcriptase polymerase
chain reaction (RT-PCR) from a nasopharyngeal swab
or other respiratory sample.
SARS-CoV-2 Community Acquired Pneumonia (CAP) with
ARDS: A patient with SARS-CoV-2 CAP with evidence
of acute respiratory distress syndrome (ARDS) defined
as bilateral opacities on a chest radiograph or computed tomographic (CT) scan not fully explained by
cardiac failure or fluid overload with PaO2/FiO2 ≤ 300
mmHg on ventilator settings that include positive endexpiratory pressure (PEEP) ≥5 cm H2O. [20]
Cardiac and cardiovascular events: The following cardiac or cardiovascular events that were present at the
time of admission or developed during hospitalization
were collected: development of heart failure, cardiac
arrest, cardiogenic shock, acute myocardial infarction,
pulmonary edema, new arrhythmia, acute worsening
of a chronic arrhythmia, cerebrovascular accident, pulmonary embolism, myocarditis, and deep vein thrombosis.
Septic Shock: Defined by persisting hypotension requiring vasopressors to maintain a mean arterial pressure
of 65 mm Hg or higher and a serum lactate level greater
than 2 mmol/L (18 mg/dL) despite adequate volume
resuscitation.[19]
Clinical outcomes: Binary outcomes evaluated included
need for IMV, admission to ICU, septic shock, ARDS,
and death. Time-to-event outcomes evaluated included
time to hospital discharge, time to initiation of mechanical ventilation, time to ICU admission, time to septic
shock, time to ARDS, and time to death.
Laboratory results: Laboratory data included in this
study included the first recorded results obtained
within 24 hrs of hospital admission for each patient.
Laboratory results included Hematology data (WBC,
neutrophil, lymphocyte and platelet counts and erythrocyte sedimentation rate [ESR]); immunological and
biochemical inflammatory markers (IL-6, C-reactive
protein [CRP], Ferritin, Procalcitonin, D-dimer, Troponin, Brain natriuretic peptide [BNP], blood urea nitrogen [BUN]; respiratory data (PaO2/FiO2) and relative viral load data (PCR Ct values for SARS-CoV-2 N1
gene).
Blood group distribution
National blood group distribution data was obtained from the American Association of Blood Banks
Technical Manual.[20] The “Expected” total blood
group distribution of the study population based on
race/ethnicity was calculated by multiplying each
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group’s relative representation in the patient population (non-Hispanic White [.48], Black [.33], Hispanic
[.12], Asian [.03], Other [.03]) by the respective ABO
blood type distribution data (%) for each race/ethnic
group in the U.S. according to the American Red Cross
[21] and then adding them together. For the “Other”
group, an average of the other groups was used.
Statistical Analysis
Patient characteristics were calculated for cases based
on blood type. Continuous variables were reported as
medians and interquartile ranges, and categorical variables were reported as frequencies and percentages.
Assessment for significant differences in patient characteristics between blood groups was conducted using
Mann-Whitney U tests and Chi-square tests of independence. Chi-square tests of homogeneity were utilized to identify potential differences in blood type proportions between national data and hospitalized SARSCoV-2 patients in Louisville, KY, as well as any differences in expected versus observed blood type distribution. P-values < 0.05 were used to denote significance for all tests conducted. Statistical analysis was
performed using R Studio Version 3.6.1.

Results
Demographics and Blood Groups
The demographic characteristics of the patients in the
study and the ABO blood group distribution is shown
in Table 1. Blood group O was the most prevalent
among the hospitalized patients (51%), followed by
group A (31%), B (14%) and AB (5%). The median age
of the overall population (n=380) was 63 years [IQR:
44,74] and 57% of the patients were male. There were
no statistically significant differences in the age of the
patients or sex distribution among the groups. Overall,
the patient population identified as 48% non-Hispanic
white (white, NH), 33% Black, 12% Hispanic, 3% Asian
and 3% Other.
Included in Table 1 are the distribution of each blood
type in each of the racial/ethnic groups. Our data
recorded a higher relative prevalence (by percentage)
of blood type O among the Hispanic patients (72%)
and higher relative prevalence of blood type A in
non-Hispanic White patients (36%), while the relative
prevalence of blood types B and AB was higher in Black
and Asian patients.
Observed vs. Expected Blood Group Distributions
At first inspection, the higher prevalence of blood
group O (51%) compared to that of group A (31%)
in our patient population seemed opposite to what
other studies had previously reported. Taking into con-
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Table 1. Demographic characteristics and blood groups.

Variable
n (%)
Age∗ (years)

All

A

AB

B

O

P-value

380 (100)
63 [44, 74]

116 (31)
66 [53, 76]

19 (5)
64 [52, 68]

52 (14)
61 [44, 74]

193 (51)
60 [41, 72]

0.133

218 (57)
162 (43)

70 (32)
46 (28)

11 (5)
8 (5)

30 (14)
22 (14)

107 (49)
86 (53)

183 (48)
125 (33)
47 (12)
13 (3)
12 (3)

66 [36]
35 [28]
9 [19]
3 [23]
3 [25]

6 [3]
10 [8]
1 [2]
2 [15]
0 [0]

22 [12]
22 [18]
3 [6]
4 [31]
1 [8]

89 [49]
58 [46]
34 [72]
4 [31]
8 [67]

Sex
Male (%)
Female (%)

0.869

Race/Ethnic Group†
White, NH
Black
Hispanic
Asian
Other
∗

Median [IQR] † Values in parentheses denote the percentage of the total population in the All column.
Values in brackets under the four different blood group columns denote the percentage of each blood
group for each racial/ethnic group.

sideration that individuals from Black, Hispanic and
other minorities are over-represented among hospitalized COVID-19 patients compared to the general population and the variability in the prevalence of different blood groups among different racial/ethnic groups,
we decided to investigate whether the blood group
distribution observed in our patient population was
influenced by its racial/ethnic composition.[21,22] To
this effect, we calculated the “expected” prevalence of
each blood type by multiplying the percentage of each
racial/ethnic group in our patient population by the reported blood group distribution in each one (see Materials and Methods). These numbers (expected distribution) were then compared with the actual (observed)
blood group distribution in our study (Table 2). No
statistically significant differences were found for the
overall distribution.
In order to show the importance of comparing the results observed in the patient population against a population of similar racial/ethnic composition, Figure 1
compares the overall observed blood group distribution with a) the National U.S. average data [20], and b)
the expected overall distribution calculated in Table 2.
As shown, while there were no statistically significant
differences between the observed and expected distributions in any of the four blood groups, the observed
distributions were significantly different from the “average” U.S. distribution for blood groups A, B and O.
Comorbidities and Blood Groups
Since many comorbidities have been established as risk
factors for COVID-19 severity [4–8], we compared the
prevalence of comorbidities by blood group (Table 3).
As expected, based on previous reports, the most common comorbidities among the hospitalized patients
were hypertension (52%), diabetes (33%) and hyperULJRI | https://ir.library.louisville.edu/jri/vol5/iss1/1

lipidemia (36%). Statistical analysis showed that there
were no significant differences in the prevalence of comorbidities among the different groups, with the exception of the higher BMI and more prevalent hypertension in patients with blood type AB.
Biomarkers and Blood Groups
Because laboratory data might give an indication of differences in disease severity, a number of hematological,
immunological and biochemical markers were investigated in the different blood groups. Table 4 summarizes information on the levels of the different markers
obtained within 24 hrs. of hospital admission. No statistically significant differences in any of the laboratory
markers, including the relative viral load measured by
the Ct value in the PCR test, were found among the different blood groups.
Outcomes and Blood Groups
The outcomes and length of hospital stay were compared among the different blood groups (Table 5).
Overall, the mortality rate was 20%, while the length
of hospital stay ranged from 4–16 days [IQR]. Consistent with the results of the laboratory markers,
there were no statistically significant differences among
blood groups for any of the recorded outcomes, including the mortality rate and the length of hospital stay.

Discussion
A better understanding of the risk factors involved
in the clinical presentation of COVID-19 is crucial
and critical given the current pandemic circumstances.
Prompted by inconsistencies in the literature regarding
the association of the ABO blood group with the risk of
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Table 2. Observed and expected∗ blood group distributions among hospitalized COVID-19
patients.

Race/Ethnic Group†
White, NH
Black
Hispanic
Asian
Other
Overall†

Fraction of Total

A

AB

B

O

0.48
0.33
0.12
0.03
0.03

36 (40)
28 (26)
19 (31)
23 (28)
25 (32)

3 (4)
8 (4)
2 (2)
15 (7)
0 (4)

12 (11)
18 (19)
6 (10)
31 (25)
8 (13)

49 (45)
46 (51)
71 (57)
31 (40)
67 (51)

1.00

31 (33)

5 (4)

14 (14)

51 (48)

∗

Based on data for blood group distribution by racial/ethnic group according to the
American Red Cross.[21] Observed and (expected) percentages of each blood
†
group are given for each racial/ethnic group.
Overall expected blood group
distribution calculated as indicated in Methods section. Comparison of observed
vs. expected overall distributions did not show statistically significant differences
(p>0.05).

Figure 1. Comparison of Observed blood group frequencies with the National U.S. average and Expected frequencies based on Racial/Ethnic
distribution in the Louisville Metro area.
*p<0.05; Natl Ave: national average.
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Table 3. Comorbidities and blood groups.

Variable

All

A

AB

B

O

P-value

380 (100)
30 [24, 37]

116 (31)
29 [24, 35]

19 (5)
37 [32, 42]

52 (14)
27 [22, 35]

193 (51)
31 [25, 37]

0.012

Smoking History
Never
Current
Former

265 (62)
40 (11)
105 (28)

69 (59)
17 (15)
30 (26)

13 (68)
0 (0)
6 (32)

30 (58)
4 (8)
18 (35)

123 (64)
19 (10)
51 (26)

Alcohol abuse (%)
Heart failure (%)
CV accident (%)
Renal disease (%)
ERSD/Dialysis (%)
Diabetes (%)
Liver Disease (%)
Cirrhosis (%)
Asthma (%)
COPD (%)
CA disease (%)
Hypertension (%)
Myoc. Infarct. (%)
Atrial Fibrillation (%)
Deep Vein Thr. (%)

29 (8)
67 (18)
64 (17)
83 (22)
34 (9)
126 (33)
10 (3)
6 (2)
36 (9)
57 (15)
66 (17)
199 (52)
28 (7)
39 (10)
21 (6)

8 (7)
18 (16)
20 (17)
26 (22)
10 (9)
36 (31)
4 (3)
3 (3)
11 (9)
16 (14)
26 (22)
69 (59)
13 (11)
15 (13)
5 (4)

2 (11)
1 (5)
2 (11)
4 (21)
3 (16)
8 (42)
0 (0)
0 (0)
1 (5)
4 (21)
2 (11)
14 (74)
0 (0)
2 (11)
1 (5)

6 (12)
10 (19)
8 (15)
13 (25)
6 (12)
21 (40)
3 (6)
0 (0)
4 (8)
3 (6)
7 (13)
30 (58)
2 (4)
4 (8)
4 (8)

13 (7)
38 (20)
34 (18)
40 (21)
15 (8)
61 (32)
3 (2)
3 (2)
20 (10)
34 (18)
31 (16)
86 (45)
13 (7)
18 (9)
11 (6)

n
BMI (median [IQR])

0.411

0.646
0.390
0.925
0.896
0.507
0.502
0.297
0.594
0.858
0.158
0.326
0.011
0.166
0.639
0.847

CV: Cardiovascular; ERSD: End stage renal disease; CA: Coronary artery.

suffering from the disease and of its severity, this study
investigated the relative frequency of different ABO
blood types among hospitalized COVID-19 patients in
the Louisville metropolitan area, as well as the potential association of the blood type with disease severity and outcomes. Our data showed that type O was
the most common blood group among the hospitalized patients (51%), followed by types A (31%), B (14%)
and AB (4%). The observed blood group distribution
among the patients was not significantly different from
the distribution that would have been expected based
on the racial/ethnic composition and without any influence of the blood group. Moreover, no significant associations were found between the blood group and comorbidities, inflammatory biomarkers or recorded outcomes, including the mortality rate and the length of
the hospital stay. Thus, our data argues against the
blood group being a significant risk factor for the severity of COVID-19.
Several initial reports from China and later from other
countries [9–11] concluded that the blood type influences the risk of COVID-19 by comparing the relative
frequencies of blood types among COVID-19 patients
with those among the general population or blood
donors in the same area. In these studies, blood type
A was reported to be over-represented while blood
type O was under-represented among COVID-19 patients in comparison with the control group, suggesting that individuals with blood type A had an increased risk while those with blood type O had a
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decreased risk for COVID-19. However, analysis of
the blood group distribution in COVID-19 patients in
our study showed that blood type O was by far the
most common (51%), considerably higher than type A
(31%). These data would seem to suggest an overrepresentation of type O and an under-representation
of type A among COVID-19 patients in our area, if compared to the national average U.S. blood group distribution (44% type O and 42% type A).[20] However, two
important facts need to be taken into consideration:
first, the racial/ethnic breakdown of the COVID-19 patient population in the U.S., including our own data
for the Louisville metro area (Table 2), show an overrepresentation of Blacks and Hispanics compared to the
national average;[22] second, blood group prevalence
varies among different racial/ethnic groups.[21] Thus,
we compared our actual “observed” blood group distribution with an “expected” distribution, calculated by
taking into account the fraction of each of the major
racial/ethnic groups in the overall patient population
and the blood group distribution in each (Table 2 and
Figure 1). Accordingly, the observed blood group distribution among the COVID-19 patients in our study
was very similar to what would be expected in a control group of a similar racial/ethnic composition and
assuming no effect of the blood group. While these results suggest that, at least in our study, blood group
was not associated with increased risk for COVID-19,
they also highlight the importance of taking into consideration the racial/ethnic composition of the population under study.
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Table 4. Inflammatory markers and blood groups.
Variable
n

All

A

AB

B

O

380 (100)

116 (31)

19 (5)

52 (14)

193 (51)

p-value

7 [5, 10]
5 [3, 8]
1 [1, 1]
195 [155, 250]

7 [5, 10]
5 [4, 8]
1 [1, 2]
201 [160, 253]

6 [4, 8]
4 [2, 6]
1 [1, 1]
202 [158, 258]

7 [5, 9]
5 [3, 7]
1 [1, 1]
184 [139, 235]

7 [5, 10]
5 [3, 8]
1 [1, 2]
194 [156, 254]

0.287
0.269
0.948
0.625

52 [30, 77]
61 [31, 135]
76 [36, 176]
0.14 [0.05, 0.57]
919 [496, 1957]
123 [39, 628]
0.02 [0.01, 0.05]
372 [140, 836]
18 [11, 33]
249 [131, 354]

60 [31, 92]
79 [41, 168]
86 [42, 191]
0.16 [0.05, 0.97]
845 [481, 1962]
292 [41, 671]
0.01 [0.01, 0.07]
322 [137, 809]
19 [12, 32]
230 [129, 350]

60 [44, 69]
47 [29, 122]
71 [45, 139]
0.14 [0.05, 0.48]
681 [441, 1240]
73 [63, 187]
0.02 [0.01, 0.04]
288 [140, 561]
21 [14, 25]
288 [216, 312]

72 [19, 100]
67 [48, 154]
58 [29, 169]
0.15 [0.08, 0.53]
1145 [748, 2850]
484 [386, 2180]
0.02 [0.01, 0.03]
585 [164, 1368]
18 [11, 41]
276 [185, 360]

44 [32, 71]
54 [24, 98]
74 [40, 172]
0.12 [0.05, 0.53]
903 [496, 1813]
92 [36, 383]
0.01 [0.01, 0.05]
360 [146, 714]
18 [11, 31]
257 [129, 357]

0.759
0.297
0.388
0.860
0.424
0.275
0.965
0.121
0.758
0.864

Blood cells (cells x 103 /mL)
WBC
Neutrophils
Lymphocytes
Platelets
Other biomarkers
ESR (mm/hr)
IL-6 (pg/mL)
CRP (mg/mL)
Procalcitonin(ng/mL)
D-dimer (ng/mL)
BNP (pg/mL)
Troponin (ng/mL)
Ferritin (ng/mL)
BUN (mg/dL)
PaO2/FiO2 ratio

All markers represent median [IQR].
ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; BNP: Brain natriuretic peptide; BUN: Blood urea nitrogen; PaO2: Partial pressure of oxygen; FiO2: fraction of inspired oxygen; N1: SARS-CoV-2 N1 gene.

Our results are consistent with other recent studies in
the U.S. that have not found an association of blood
group with disease severity or outcomes in COVID19 patients.[15–17] However, the reasons for the discrepancies with those studies where an effect of blood
group was found are not completely clear. The relative genetic diversity of the different populations under study, as well as the population chosen as “control” in each case, could be involved. The U.S. population is very diverse, and it is possible that such genetic diversity may mask an effect of blood group or
make it more difficult to detect. Moreover, as evidenced
by the different conclusions obtained when comparing
our observed results with either the national U.S. average or the expected blood group distribution, the use
of the appropriate control group is obviously a key factor. One of the main strengths of this study is that
the observed ABO blood group distribution is consistent with the racial/ethnic breakdown of our patient
population, thus highlighting the well-known fact that
the spread of COVID-19 in the U.S. has disproportionately affected minority populations, including African
Americans and Hispanics.[22]
Another important issue is that of the potential association of blood group with the severity and mortality of
COVID-19. To tackle this question, our study initially
analyzed the presence of a variety of comorbidities that
may potentially influence the severity of the disease in
infected persons, separating our patient population by
blood group (Table 3). Our data analysis indicated that
the prevalence of different comorbidities among patients with different blood groups was not significantly
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different, thus suggesting no differences in predisposing conditions. The only exception found was that of a
higher BMI and more frequent incidence of hypertension in patients with blood type AB. However, these results were likely influenced by the reduced number of
patients (n=19) with this blood type, thus precluding
any conclusions or generalizations.
Our study also investigated whether patients of different blood groups differed in terms of hematologic, immunologic, biochemical and respiratory markers associated with the severity of the COVID-19 disease. As
shown by our results, no statistically significant differences in any of these markers were found among
the different patient groups, suggesting no significant
effect of the blood group on the severity of the disease. In addition, our study analyzed the incidence
of a variety of disease complications and outcomes
among patients of different blood groups, including
mortality and length of hospital stay. As shown in Table 5 and consistent with the results of the inflammatory biomarkers, no significant differences were found
among the different groups, indicating, again, no significant association of blood group with the risk of developing severe manifestations of the disease or death.
Although the number of cases included in our study
(n=380) is similar to other studies reporting on the association of blood group with COVID-19, it is still relatively small compared to other larger studies. Based
on the relatively small number of cases, we chose not
to include the Rh blood group to further divide our patient population, as that would have resulted in groups
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Table 5. Outcomes and blood groups.

Variable
n
Septic Shock (%)
ARDS (%)
Cardiac events* (%)
ICU admission
IMV
Mortality (%)

All

A

AB

B

O

P-value

380 (100)
61 (16)
70 (18)
47 (12)
165 (43)
114 (30)
76 (20)

116 (31)
20 (17)
23 (20)
14 (12)
52 (45)
36 (33)
22 (19)

19 (5)
2 (11)
3 (16)
2 (11)
6 (32)
5 (31)
4 (21)

52 (14)
9 (17)
8 (15)
3 (6)
22 (42)
13 (29)
12 (23)

193 (51)
30 (16)
36 (19)
28 (14)
85 (44)
60 (36)
38 (20)

0.885
0.904
0.403
0.749
0.850
0.938

8 [4, 16]
4 [1, 7]
3 [1, 7]
1 [0, 3]
2 [1, 4]
11 [6, 15]

9 [4, 18]
4 [1, 8]
4 [1, 10]
1 [0, 3]
2 [1, 4]
10 [6, 16]

6 [6, 11]
2 [1, 3]
1 [0, 2]
1 [0, 2]
1 [1, 3]
12 [10, 12]

8 [4, 19]
5 [1, 6]
5 [3, 9]
0 [0, 3]
3 [1, 5]
8 [6, 16]

8 [4, 15]
4 [2, 8]
3 [1, 5]
1 [0, 3]
2 [1, 4]
11 [6, 15]

0.495
0.714
0.296
0.716
0.725
0.973

Times (days—median [IQR])
Hospital stay
To Septic Shock
To ARDS
To ICU admission
To IMV
To death
∗

Cardiac events include heart failure, cardiac arrest, acute myocardial infarction, cerebrovascular accident
and pulmonary embolism. ICU: Intensive care unit, IMV: Invasive mechanical ventilation.

with a very low number of patients for the Rh- blood
groups. A further limitation is the fact that our cases
included only patients admitted to the hospital, and
thus, they are not necessarily representative of the overall population in our community that tested positive for
SARS-CoV-2. In this regard, our population would represent those individuals that developed symptoms severe enough to be admitted to the hospital. However, if
any of the blood groups had initially had an influence
on the risk of infection, we would have expected to see
such bias reflected in the patient population admitted
to the hospital. Rather, our numbers were consistent

with the racial/ethnic distribution of the admitted patients.
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In conclusion, our study found no significant differences in the prevalence of the ABO blood type among
hospitalized patients with COVID-19 in the Louisville,
KY, area when compared to a population of similar
racial/ethnic composition. Moreover, our study did
not detect significant associations of blood group with
a variety of hematologic, immunologic, biochemical
and respiratory markers of disease severity, nor with
the frequency of different disease outcomes, including
mortality.
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Mark Burns, MD
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Deepti Deepti
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Sherin Elgohary
Omar Fahmy
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Evelyn Exposito Gonzalez
Bibodh Jung Karki
Ahsan Masood Khan
Simra Kiran
Pavani Nathala
Ramya Praveen Kumar
Balaji Sekaran
Ahmed Ali Shebl
Nishita Tripathi
Data Management &
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Stephen Furmanek, MPH (Lead)
Thomas Chandler, MPH
Meredith Cahill
Victoria Clemons
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Laboratory Unit
Leslie Wolf, PhD (Lead)
Biorepository Unit
Subathra Marimuthu, PhD (Lead)
Quality Assurance Unit
Mohammed Tahboub (Lead)
Raghava Sekhar Ambadapoodi
Ahmed Gana
Ahmed Omran
Sahaj Hardeep Singh
Harideep Samanapally
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Morgan Stanley (Lead)
Mohamed Abdelnabi
Mahmoud Abdelsamia
Lakshmi Cherukuwada
Arashpreet Chhina
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Salman Elgharbawy
Durgaprasad Gadireddi
Shivam Gulati
Zahid Imran
Divya Menghani
Lucia Puga Sanchez
Nida Qadir
Adnan Qureshi
Ashraf Rjob
Syed Shah
Hammad Tanzeem
Medical Writing Unit
Forest Arnold, DO (Lead)
Informatics Unit
William Mattingly, PhD (Lead)
Matthew Grassman
Rakhi Shah
Gregory Lindauer
Marketing Unit
Emily Just, MA (Lead)
Tessa Chilton
Alex Glynn
Chaireth Jones
Elizabeth Wolfe
Epidemiology Unit
T’shura Ali, PhD (Lead)
Education & Training Unit
Kimberley Buckner (Lead)
University Outreach Unit
Ruth Carrico, PhD (Lead)
Community Outreach Unit
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Administration Unit
Emily Just, MA (Lead)
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